期刊文献+

乙型肝炎病毒核心区基因免疫小鼠细胞免疫应答研究 被引量:2

The immune response in Balb/c mice immunized with hepatitis B virus core DNA based vaccine
原文传递
导出
摘要 目的观察小鼠对HBV核心区基因疫苗的免疫应答。方法将经过基因修饰的乙型肝炎病毒核心区基因定向克隆于真核表达载体(pcDNA3),构建成HBV核心区基因疫苗(pcDNA-HBV),给Balb/c小鼠多点肌肉注射,2周后追加免疫一次,用竞争抑制酶联法及MTT法检测小鼠血清抗-HBc及脾细胞对HBcAg的特异性增殖反应。结果免疫接种2周后小鼠血清抗-HBc均阳性,持续12周以上,脾细胞对HBcAg的刺激指数明显高于对照组(P<0.05)。结论pcDNA-HBV在Balb/c小鼠体内既可诱导体液免疫应答。 Objective To study immune response in mice against the HBV core DNA based vaccine.Methods The modificated HBc gene with its stem and loopstructure was inserted into the eukaryotic expression vector (pcDNA HBV).The Balb/c mice were immunized by multiple sites intramuscular injection with pcDNA HBV and pcDNA3 respectively.Each mouse was boosted after 2 weeks.The anti HBc Ab was detected by ELISA,meanwhile,the stimulation index of spleencytes to HBcAg were measured by MTT method.Results The anti HBc in mice immunized with pcDNA HBV became and maintained to be positive for at least 12 weeks.The stimulation index of spleencytes to HBcAg were significantly higher than that of mice injected with pcDNA3.Conclusion The investigation demonstrated that pcDNA HBV could generated humoral and cellular immune response in Balb/c mice.
出处 《中华传染病杂志》 CAS CSCD 北大核心 1998年第4期216-218,共3页 Chinese Journal of Infectious Diseases
基金 国家自然科学基金
关键词 乙型肝炎病毒 核心区 基因免疫 细胞免疫应答 Hepatitis B Virus Gene,immune response
  • 相关文献

参考文献3

  • 1邓涛,中国公共卫生学报,1998年,17卷,13页
  • 2邓涛,国外医学.病毒学分册,1996年,3期,88页
  • 3Wang B,Proc Natl Acad Sci USA,1993年,90卷,4156页

同被引文献24

  • 1Weeratna RD, McCluskie MJ, Comanita L, et al. Optimization strategies for DNA Vaccines. Inter Virol,2000,43:218-226.
  • 2Thermet A, Christine R, Zoulim F, et al. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine, 2003,21:659-662.
  • 3Prince AM, Whalen R, Brotman B, et al. Successful nucleic acid based immunication of newborn chimpanzees against hepatitis B virus. Vaccine,1997,15:916.
  • 4Tacket CO, Roy MJ, Widera G. Phage 1 safety and immune respons e studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine,1999,17:2826-2829.
  • 5Michael ML, Goldbeck C, Pertile T, et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future. Vaccine,2001,19:2395-2399.
  • 6Swain WE, Heydenburg-Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Dev Biol(Basel),2000,104:115-119.
  • 7Haworth R, Pilling AM. The PCR assay in the preclinical safety evaluation of nucleic acid medicines. Hum Exp Toxicol,2000,19:267-276.
  • 8Loirat D, Li Z, Mancini M, et al. Muscle specific expression of HBsAg: no effect on DNA-raised immune response. Virology,1999,260:74-83.
  • 9Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol,2000,164:4635-4640.
  • 10You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res,2001,61:3704-3711.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部